U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07084259) titled 'Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study' on July 16.
Brief Summary: This pilot study aims to evaluate whether a single dose of PCSK9 inhibitor administered after percutaneous coronary intervention (PCI) can improve long-term cardiovascular outcomes in patients with high post-PCI lipid core burden, as assessed by NIRS-IVUS. The study will assess major adverse cardiovascular events (MACE) over a 12-month follow-up period.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Coronary Artery Disease
Intervention:
DRUG: PCSK9 inhibitor
Single dose of subcutaneous admini...